阅读说明：本技术 洛美利嗪在制备抗结肠癌药物中的应用 (Application of lomerizine in preparation of anti-colon cancer drug ) 是由 许雯雯 廖化新 黄云娜 于 2019-10-24 设计创作，主要内容包括：本发明公开了洛美利嗪在制备抗结肠癌药物中的应用。本发明首次发现洛美利嗪可以抑制结肠癌的生长,可抑制结肠癌细胞的增殖。并且,洛美利嗪抑制结肠癌细胞的生长速度随着洛美利嗪浓度的增加而减慢,高浓度的洛美利嗪能够显著抑制结肠癌细胞的增殖。洛美利嗪是一种已批准上市的药物,较开发新药物而言成本低,无明显毒副作用,将其用来治疗结肠癌,能够为结肠癌的治疗提供新的药物来源。(The invention discloses an application of lomerizine in preparing a colon cancer resistant medicament. The invention discovers for the first time that lomerizine can inhibit the growth of colon cancer and can inhibit the proliferation of colon cancer cells. And the growth rate of the lomerizine for inhibiting the colon cancer cells is reduced along with the increase of the concentration of the lomerizine, and the high concentration of the lomerizine can obviously inhibit the proliferation of the colon cancer cells. The lomerizine is an approved drug on the market, has low cost and no obvious toxic or side effect compared with the development of a new drug, is used for treating colon cancer, and can provide a new drug source for treating the colon cancer.)

1. Application of lomerizine in preparing anti-colon cancer drugs.

2. The use of lomerizine of claim 1 in the preparation of an anti-colon cancer medicament, wherein: the anti-colon cancer drug contains at least one of lomerizine and physiologically acceptable salts thereof.

3. The use of lomerizine of claim 1 in the preparation of an anti-colon cancer medicament, wherein: the colon cancer resisting medicine contains a pharmaceutically acceptable carrier or auxiliary materials.

4. The use of lomerizine of claim 3 in the preparation of an anti-colon cancer medicament, wherein: the carrier is at least one of a microcapsule, a microsphere, a liposome and a nanoparticle.

5. The use of lomerizine of claim 3 in the preparation of an anti-colon cancer medicament, wherein: the auxiliary materials are at least one of cosolvent, solubilizer, emulsifier, preservative, wetting agent, surfactant, sustained-release agent, excipient, disintegrating agent and lubricant.

6. The use of lomerizine of claim 1 in the preparation of an anti-colon cancer medicament, wherein: the colon cancer resisting medicine is prepared into various dosage forms by adopting a conventional method.

7. The use of lomerizine of claim 6 in the preparation of an anti-colon cancer medicament, wherein: the colon cancer resisting medicine is an oral preparation.

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to application of lomerizine in preparation of a colon cancer resistant medicine.

Background

Colon cancer is the fourth largest cancer causing death in humans, and its conventional treatments include surgery, radiation therapy and chemotherapy. Despite the progress of chemotherapy, the existing anticancer drugs still have serious adverse reactions. Therefore, the search for a safe and effective novel drug and the provision of a new treatment means for the treatment of colon cancer become an urgent problem to be solved.

Lomerizine is a drug that has been clinically approved for marketing in japan. It is reported that the therapeutic effect on migraine reaches 50-75%, and has the advantages of no serious adverse reaction, good clinical tolerance, higher selectivity on cerebral circulation than similar drugs, and the like, so the medicine is taken as the first-line medicine for preventing migraine in Japan since 1999.

The current surge in the price of new tumor drugs is reducing the chances of patients obtaining the latest effective anti-cancer therapies, and the drugs that have already been clinically approved are being reused, providing a potentially more economical, faster, and safer treatment for tumors. At present, no relevant literature and patent reports about the effect of lomerizine on colon cancer cells are reported.

Disclosure of Invention

The invention aims to overcome the defects in the prior art and provide the application of lomerizine in preparing anti-colon cancer drugs.

The purpose of the invention is realized by the following technical scheme: application of lomerizine in preparing anti-colon cancer drugs.

The anti-colon cancer drug contains at least one of lomerizine and physiologically acceptable salts thereof.

The colon cancer resisting medicine contains a pharmaceutically acceptable carrier or auxiliary materials.

The carrier is preferably at least one of microcapsule, microsphere, liposome and nanoparticle.

The auxiliary materials are preferably at least one of cosolvent, solubilizer, emulsifier, preservative, wetting agent, surfactant, sustained-release agent, excipient, disintegrating agent and lubricant.

The colon cancer resisting medicine can be prepared into various dosage forms by adopting a conventional method, such as tablets, granules, capsules, pills and other oral dosage forms.

Compared with the prior art, the invention has the following advantages and effects:

1. the inventor of the invention combines in vitro and in vivo experiments to discover that lomerizine can inhibit the growth of colon cancer for the first time.

2. The lomerizine can inhibit the proliferation of colon cancer cells, the growth rate of the colon cancer cells HT29 and DLD-1 is reduced along with the increase of the concentration of the lomerizine, and the high concentration of the lomerizine can obviously inhibit the proliferation of the colon cancer cells HT29 and DLD-1.

3. The lomerizine can obviously inhibit the tumorigenic capacity of colon cancer cells and has no obvious toxic or side effect.

4. The lomerizine is an approved drug on the market, has low cost and high safety compared with the development of a new drug, is used for treating colon cancer, and can provide a new drug source for treating the colon cancer.

Drawings

FIG. 1 is a graph showing the results of CCK-8 experiments on colon cancer cells HT29 and DLD-1 at different concentrations of lomerizine.

FIG. 2 is a graph showing the results of the monoclonal formation experiments of colon cancer cells HT29 and DLD-1 at different concentrations of lomerizine.

FIG. 3 is a photograph of tumors of colon cancer cell DLD-1 in nude mice at different concentrations of lomerizine.

FIG. 4 is a graph showing the tumor volume change of colon cancer cell DLD-1 tumor formation in nude mice at different concentrations of lomerizine.

FIG. 5 is a graph of weight change in nude mice at different concentrations of lomerizine.

FIG. 6 is a graph showing the results of ALT and AST routine tests performed on blood of nude mice at different concentrations of lomerizine.

DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION

The present invention will be described in further detail below with reference to specific examples and drawings, but the embodiments of the present invention are not limited thereto. Those who do not specify the conditions are performed according to the conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.

Human colon cancer cells HT29, DLD-1 were purchased from the cell bank of the culture Collection of type culture Collection of the Chinese academy of sciences.